Patents by Inventor Yuji Kazuta

Yuji Kazuta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210255191
    Abstract: Disclosed is: a fluorescent dye comprising a compound, a tautomer of the compound, or a salt of the compound or the tautomer; a labeled composite substance comprising the fluorescent dye and a composite substance which are bonded to each other; a composition containing the fluorescent dye or the labeled composite substance; and a method for acquiring information about a substance of interest by a super-resolution microscopy.
    Type: Application
    Filed: February 1, 2021
    Publication date: August 19, 2021
    Applicants: Eisai R&D Management Co., Ltd., SYSMEX CORPORATION
    Inventors: Daiki HARA, Takafumi Motoki, Yuji Kazuta, Yoshihiko Norimine, Hiroyuki Amino, Masatoshi Suganuma, Shingo Fujiyama, Kazuto Yamashita, Masaya Okada, Yoichi Nishikawa, Shigeki Iwanaga
  • Patent number: 9610262
    Abstract: The present invention is directed to a method of treating pain comprising the administering the following 1-indansulfamide compounds: N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (?)-N-(7-chloro-2,2,5-trifluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, N-[(1S)-2,2-difluoro-7-methyl-2,3-dihydro-1H-inden-1-yl]sulfamide, and N-[(1S)-2,2,5-trifluoro-7-methyl-2,3-dihydro-1H-inden-1-yl]sulfamide.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: April 4, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Hiroyuki Higashiyama, Yuji Kazuta, Keisuke Hashimoto
  • Publication number: 20160303058
    Abstract: A medicine comprising a 1-indansulfamides compound such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, or N-[(1S)-2,2-difluoro-7-methyl-2,3-dihydro-1H-indene-1-yl]sulfamide or a pharmaceutically acceptable salt thereof, has an analgesic effects in the mouse hot-plate test and rat constriction nerve injury model and thus holds promise as a therapeutic agent for acute and chronic pain.
    Type: Application
    Filed: December 17, 2014
    Publication date: October 20, 2016
    Inventors: Hiroyuki Higashiyama, Yuji Kazuta, Keisuke Hashimoto
  • Patent number: 9416109
    Abstract: The present disclosure provides compounds and methods that are useful for the preparation of compounds useful as orexin-2 receptor antagonists.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: August 16, 2016
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: George Anthony Moniz, Annie Zhu Wilcoxen, Farid Benayoud, Jaemoon Lee, Huiming Zhang, Taro Terauchi, Ayumi Takemura, Yu Yoshida, Toshiaki Tanaka, Keiichi Sorimachi, Yoshimitsu Naoe, Yuji Kazuta
  • Patent number: 9018260
    Abstract: Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 28, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yuji Kazuta, Toru Watanabe, Keiichi Sorimachi, Minako Saito, Yoichi Kita, Toshiaki Tanaka, Hiroyuki Higashiyama, Takahisa Hanada, Tetsuyuki Teramoto, Takashi Kosasa, Yukio Ishikawa
  • Publication number: 20150025237
    Abstract: The present disclosure provides compounds and methods that are useful for the preparation of compounds useful as orexin-2 receptor antagonists.
    Type: Application
    Filed: February 14, 2013
    Publication date: January 22, 2015
    Inventors: George Anthony Moniz, Annie Zhu Wilcoxen, Farid Benayoud, Jaemoon Lee, Huiming Zhang, Taro Terauchi, Ayumi Takemura, Yu Yoshida, Toshiaki Tanaka, Keiichi Sorimachi, Yoshimitsu Naoe, Yuji Kazuta
  • Publication number: 20140371319
    Abstract: Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.
    Type: Application
    Filed: June 17, 2013
    Publication date: December 18, 2014
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yuji Kazuta, Toru Watanabe, Keiichi Sorimachi, Minako Saito, Yoichi Kita, Toshiaki Tanaka, Hiroyuki Higashiyama, Takahisa Hanada, Tetsuyuki Teramoto, Takashi Kosasa, Yukio Ishikawa
  • Patent number: 8268848
    Abstract: A cyclopropane compound represented by the following formula (A) or a pharmaceutically acceptable salt thereof has orexin receptor antagonism, and therefore has a potencial of usefulness for the treatment of sleep disorder for which orexin receptor antagonism is effective, for example, insomnia: wherein Q represents —CH— or a nitrogen atom, R1a and R1b each independently represent a C1-6 alkyl group and the like, R1c represents a hydrogen atom and the like, R2a, R2b, R2c and R2d each independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group and the like, R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom and the like, and R3d represents a hydrogen atom and the like.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: September 18, 2012
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Taro Terauchi, Ayumi Takemura, Takashi Doko, Yu Yoshida, Toshiaki Tanaka, Keiichi Sorimachi, Yoshimitsu Naoe, Carsten Beuckmann, Yuji Kazuta
  • Publication number: 20120165339
    Abstract: A cyclopropane derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof has orexin receptor inhibitory action, and thus, is extremely useful as an agent for preventing or treating sleep disorder or dyssomnia caused by orexin, including insomnia as a typical example: wherein A1, A2 and A3 each independently represent an aryl group, a heterocyclyl group or the like, R1, R2 and R3 each independently represent a hydrogen atom, a C1-6 alkyl group or the like, X represents an oxygen atom or the like, and L represents a bond or the like.
    Type: Application
    Filed: December 20, 2011
    Publication date: June 28, 2012
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Taro Terauchi, Ayumi Takemura, Yuji Kazuta, Fumihiro Ozaki, Takashi Doko, Yu Yoshida, Toshiaki Tanaka, Keiichi Sorimachi, Yoshimitsu Naoe, Carsten Beuckmann
  • Publication number: 20120095031
    Abstract: A cyclopropane compound represented by the following formula (A) or a pharmaceutically acceptable salt thereof has orexin receptor antagonism, and therefore has a potencial of usefulness for the treatment of sleep disorder for which orexin receptor antagonism is effective, for example, insomnia: wherein Q represents —CH— or a nitrogen atom, R1a and R1b each independently represent a C1-6 alkyl group and the like, R1c represents a hydrogen atom and the like, R2a, R2b, R2c and R2d each independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group and the like, R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom and the like, and R3d represents a hydrogen atom and the like.
    Type: Application
    Filed: September 20, 2011
    Publication date: April 19, 2012
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Taro Terauchi, Ayumi Takemura, Takashi Doko, Yu Yoshida, Toshiaki Tanaka, Keiichi Sorimachi, Yoshimitsu Naoe, Carsten Beuckmann, Yuji Kazuta
  • Publication number: 20090318690
    Abstract: Disclosed is a compound represented by the general formula (I) or a salt thereof: wherein any one of R1, R2 and R3 represents a group represented by the formula: —(CH2)m-NR11R12 (wherein m is 1 or 2; and R11 and R12 independently represent a hydrogen atom or a C1-6 alkyl group or may, together with a nitrogen atom to which R11 and R12 are bound, form a 4- or 5-membered cyclic group); the remaining two or R1, R2 and R3 independently represent a group represented by the formula: —(O)n-R21 (wherein n is 0 or 1; and R21 represents a hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or the like); and R4 represents a C1-6 alkyl group which may have a substituent or the like.
    Type: Application
    Filed: April 27, 2007
    Publication date: December 24, 2009
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi Sasaki, Kohshi Ueno, Yuichi Suzuki, Shinichi Hamaoka, Daisuke Shimmyo, Yoshinori Takahashi, Toshiki Kurokawa, Yuji Kazuta, Hiroo Ogura, Tatsuto Fukushima